In the EU the incidence of angiosarcoma is 0.01 per 10,000, accounting for an estimated 508 cases annually. About TRACON TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. useful linkThe Companys clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. The Company is also developing two programs in-licensed from Janssen Pharmaceutica N.V. TRC253, a small molecule inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that may display drug resistance, which is intended for the treatment of men with prostate cancer, and TRC694, a small molecule inhibitor of NF-kB inducing kinase (NIK), which is intended for the treatment of patients with hematologic malignancies, including myeloma. To learn more about TRACON and its product candidates, visit TRACON’s website at www.traconpharma.com . Forward-Looking Statements Statements made in this press release regarding matters that are not historical facts are forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forwardlooking statements. Such statements include, but are not limited to, statements regarding the potential benefits that may be derived from the SPA, TRACON’s plans to further develop its product candidates and expectations regarding the initiation, design and timing of future clinical trials by TRACON or third parties. click here for infoRisks that could cause actual results to differ from those expressed in these forwardlooking statements include: risks associated with clinical development; whether TRACON or others will be able to complete or initiate clinical trials on TRACONs expected timelines, if at all; whether TRACON will realize expected benefits from the SPA; the fact that the SPA does not guarantee regulatory approval, even if the planned Phase 3 trial meets the agreed-upon endpoints; the fact that future preclinical studies and clinical trials may not be successful or otherwise consistent with results from prior studies; potential changes in regulatory requirements in the United States and foreign countries; TRACONs reliance on third parties for the development of its product candidates, including the conduct of its clinical trials and manufacture of its product candidates; whether TRACON will be able to obtain additional financing; and other risks described in TRACONs filings with the Securities and Exchange Commission under the heading Risk Factors.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/tracon-pharmaceuticals-receives-special-protocol-130000684.html